Semax is a synthetic analogue of the ACTH(4-7) fragment with a Pro-Gly-Pro extension that prevents rapid degradation. Research focuses on nootropic effects, neuroprotection, and BDNF upregulation.
Standard Research Dosage
Intranasal: 200–600 mcg per dose, 1–2x daily (most common route). Subcutaneous: 200–500 mcg per injection. Intranasal administration is preferred for CNS-targeted research due to direct olfactory nerve transport.
BDNF and Neuroprotection
Semax upregulates BDNF (brain-derived neurotrophic factor) expression in the hippocampus and cortex. Animal studies show neuroprotective effects in stroke models, with reduced infarct size and improved neurological outcomes.
Cognitive Research
Russian clinical studies show Semax improves attention, memory, and cognitive performance in subjects with cognitive impairment. It is approved in Russia for stroke treatment and cognitive enhancement.